Pulmonary Toxicity in Patients With Advanced-Stage Germ Cell Tumors Receiving Bleomycin With and Without Granulocyte Colony Stimulating Factor
Authors:
- Craig R. NicholsCNCraig R. Nichols
- Lawrence H. EinhornLELawrence H. Einhorn
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.Journal of Clinical Oncology, 1995
- Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effectBritish Journal of Cancer, 1995
- Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphomaBritish Journal of Cancer, 1994
- Pulmonary toxicity and bleomycinThe Lancet, 1994
- Possible toxicity with the association of G-CSF and bleomycinThe Lancet, 1994
- Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergyThe Lancet, 1993
- Drug-induced Pulmonary DiseaseChest, 1992
- Bleomycin-induced Pulmonary Function AbnormalitiesChest, 1992
- Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.Journal of Clinical Oncology, 1991
- Bleomycin-Induced Pulmonary ToxicityClinics in Chest Medicine, 1990